Get started
Author

Xing‐yu Cao

Observed names: Xing-Yu Cao, Xing-yu Cao
ORCID: 0000-0002-3142-6456
Observed ORCID: 0000-0002-3142-6456
OpenAlex ID: A5102747620
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy
2024 · Xing‐yu Cao, Jian‐ping Zhang, et al. · British Journal of Haematology · 16
PDF
Low SOS/VOD Risk with Inotuzumab Ozogamicin as a Bridging Strategy to Second Allogeneic HSCT: A Real-World Study in Post-Transplant Relapsed B-ALL
2026 · Fei Pan, Jing Long, et al. · Transplantation and Cellular Therapy · 2
Real-world safety and efficacy of blinatumomab for EBV viremia and EBV-related PTLD after allogeneic hematopoietic stem cell transplantation
2026 · Yun-chao Su, Jing Long, et al. · Bone Marrow Transplantation
Prognostic Associations of Molecular MRD and Genomic Features in ZNF384-Rearranged B-ALL Undergoing Allo-HSCT
2026 · Xue-Shuang Zhang, Yan-Li Zhao, et al. · Transplantation and Cellular Therapy
Contrasting relapse rate associated with the absence of HLA-A3/A11 in T cell-replete haploidentical transplantation
2026 · Xiang-Feng Tang, Hai-Fei Zhou, et al. · Frontiers in Immunology
PDF
Disease biology rather than donor type determines transplant outcomes in KMT2A-rearranged AML
2026 · Xue-Shuang Zhang, Yan-Li Zhao, et al. · Annals of Hematology
Gemtuzumab Ozogamicin-Containing Salvage Strategies as a Bridge to Second Allogeneic Hematopoietic Stem Cell Transplantation in Post-transplant Relapsed AML
2026 · Xiao-hong Liu, Jing Long, et al. · Transplantation and Cellular Therapy
Peritransplant KMT2A-r Molecular MRD Dynamics and Relapse Timing Stratify Outcomes After Allo-HSCT in CR1 Acute Leukemia
2026 · Bai-Qing Sun, Yan-Li Zhao, et al. · Transplantation and Cellular Therapy
Long-Term Outcomes of Second Allogeneic Transplantation Following CD7 CAR-T in Remission for T-Cell Acute Lymphoblastic Leukemia or Lymphoma
2026 · Xing-yu Cao, Jian-ping Zhang, et al. · Transplantation and Cellular Therapy
Superior long-term survival with acceptable safety of ATG/G-CSF–based haplo-HSCT with intensified BU+MEL/TT conditioning in CR Pediatric Non-DS–AMKL
2026 · Fei Pan, Jing Long, et al. · Frontiers in Oncology
PDF
Augmented myeloablative conditioning with olaparib in allogeneic hematopoietic stem cell transplantation for relapsed/refractory RUNX1::RUNX1T1-positive acute myeloid leukemia
2026 · Song Xue, Wei Ma, et al. · Frontiers in Oncology
PDF
Works count: 11
Citation count: 18
H-index: 2
I10-index: 1
Year
Topic
Type